Dacomitinib
Back to searchMolecule Structure
Scientific Name
Dacomitinib
Description of the Drug
Dacomitinib is a medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11963
http://www.drugbank.ca/drugs/DB11963
Brand Name(s)
Not Available
Company Owner(s)
Pfizer Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Epidermal growth factor receptor erbB1 | SINGLE PROTEIN | INHIBITOR | CHEMBL203 |
Receptor protein-tyrosine kinase erbB-4 | SINGLE PROTEIN | INHIBITOR | CHEMBL3009 |
Receptor protein-tyrosine kinase erbB-2 | SINGLE PROTEIN | INHIBITOR | CHEMBL1824 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL25637 | ||
DrugBank | DB11963 | ||
PubChem: Thomson Pharma | 16613030 | ||
PubChem | 11511120 | ||
LINCS | LSM-42808 | ||
Nikkaji | J3.341.567B | ||
PDBe | 1C9 | ||
BindingDB | 112499 | ||
EPA CompTox Dashboard | DTXSID50149493 | ||
DrugCentral | 5297 | ||
Brenda | 213443 | ||
ChemicalBook | CB22566418 | ||
Guide to Pharmacology | 7422 | ||
rxnorm | DACOMITINIB ANHYDROUS | VIZIMPRO | DACOMITINIB |
ChEBI | 132268 | ||
ZINC | ZINC000072266312 |